Compare Nasdaq100 ETF (QQQ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Tango Therapeutics Inc. — how do they compare? Nasdaq100 ETF trades at $719.7 (market cap $501.32B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Nasdaq100 ETF is far larger — about 133.7× Tango Therapeutics Inc.'s market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 163 Days and Tango Therapeutics Inc. for 0 Days on average.
| QQQ | TNGX | |
|---|---|---|
Market Cap | $501.32B | $3.75B |
Volume | 28,524,918 | 9,619,106 |
52-Week High | $759.66 | $32.90 |
52-Week Low | $558.34 | $7.50 |
Typical Hold Time | 163 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $728.95, down 2.28% today amid broader market pressure. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The ETF faces mixed analyst sentiment with a 50/50 split between buy and sell recommendations. Recent news highlights concerns about AI market sustainability and Fed rate impacts, though historical patterns suggest potential post-midterm election strength.
QQQ's concentrated tech exposure offers growth potential through AI-driven innovation but carries valuation risks amid elevated market levels. Key risks include interest rate sensitivity and sector concentration, while institutional expansion through new international ETFs signals long-term confidence in the innovation theme.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
